CD19 and diffuse large B-cell lymphoma: A real-world experience applying the grading system to a cohort of 549 patients treated with BCMA- or CD19-directed CAR T-cells for refractory B-cell malignancies (MM, DLBCL, MCL) found that severe ICAHT was associated with a higher rate of severe infections and inferior survival outcomes (41).